Dianthus Therapeutics, Inc. (DNTH)

Market Cap	5.10B +809.8%
Revenue (ttm)	1.34M -79.5%
Net Income	-173.66M
EPS	-4.17
Shares Out	54.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	857,830
Open	94.29
Previous Close	94.34
Day's Range	90.52 - 97.48
52-Week Range	17.88 - 98.70
Beta	0.09
Analysts	Strong Buy
Price Target	127.67 (+36.78%)
Earnings Date	Aug 7, 2026

About DNTH

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell functio...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 92
• Stock Exchange: NASDAQ
• Ticker Symbol: DNTH
• Website: https://dianthustx.com

Financial Performance

In 2025, Dianthus Therapeutics's revenue was $2.04 million, a decrease of -67.35% compared to the previous year's $6.24 million. Losses were -$162.34 million, 91.1% more than in 2024.

Analyst Summary

According to 15 analysts, the average rating for DNTH stock is "Strong Buy." The 12-month stock price target is $127.67, which is an increase of 36.78% from the latest price.

Price Target

$127.67

(36.78% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jul 7, 2026

Data Sources Report a data error